IFP Advisors Inc cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 14.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,946 shares of the company’s stock after selling 339 shares during the period. IFP Advisors Inc’s holdings in Neurocrine Biosciences were worth $196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of Neurocrine Biosciences by 1.9% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,430 shares of the company’s stock worth $627,000 after acquiring an additional 120 shares during the last quarter. Securian Asset Management Inc. boosted its stake in Neurocrine Biosciences by 1.4% during the fourth quarter. Securian Asset Management Inc. now owns 8,834 shares of the company’s stock worth $1,055,000 after buying an additional 121 shares during the last quarter. Larson Financial Group LLC boosted its stake in Neurocrine Biosciences by 6.7% during the third quarter. Larson Financial Group LLC now owns 1,940 shares of the company’s stock worth $206,000 after buying an additional 122 shares during the last quarter. MML Investors Services LLC boosted its stake in Neurocrine Biosciences by 1.8% during the third quarter. MML Investors Services LLC now owns 7,092 shares of the company’s stock worth $753,000 after buying an additional 123 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in Neurocrine Biosciences by 14.6% during the fourth quarter. Parallel Advisors LLC now owns 964 shares of the company’s stock worth $115,000 after buying an additional 123 shares during the last quarter. 92.58% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
NBIX has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price objective on Neurocrine Biosciences from $120.00 to $115.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 7th. Citigroup reduced their target price on Neurocrine Biosciences from $127.00 to $122.00 in a research report on Thursday, May 4th. Mizuho reduced their target price on Neurocrine Biosciences from $116.00 to $111.00 in a research report on Thursday, May 4th. Cantor Fitzgerald reduced their target price on Neurocrine Biosciences from $132.00 to $127.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 7th. Finally, Canaccord Genuity Group upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $124.00 to $132.00 in a research report on Thursday, March 30th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $125.21.
Insiders Place Their Bets
Neurocrine Biosciences Price Performance
Shares of NASDAQ NBIX opened at $97.82 on Friday. The stock’s 50-day moving average is $99.79 and its two-hundred day moving average is $109.19. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.83 and a quick ratio of 3.74. Neurocrine Biosciences, Inc. has a 1-year low of $80.50 and a 1-year high of $129.29. The company has a market cap of $9.54 billion, a price-to-earnings ratio of 163.04, a price-to-earnings-growth ratio of 1.20 and a beta of 0.49.
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last issued its quarterly earnings results on Monday, February 6th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.15 by $0.09. Neurocrine Biosciences had a return on equity of 4.03% and a net margin of 4.00%. The company had revenue of $412.00 million for the quarter, compared to the consensus estimate of $408.96 million. During the same quarter in the prior year, the business earned ($0.08) EPS. Neurocrine Biosciences’s revenue was up 32.1% on a year-over-year basis. Analysts forecast that Neurocrine Biosciences, Inc. will post 1.82 EPS for the current fiscal year.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on Neurocrine Biosciences (NBIX)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.